Arylsulfatase B Galsulfase
Arylsulfatase B Galsulfase Uses, Dosage, Side Effects, Food Interaction and all others data.
Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Arylsulfatase B Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. The recombinant protein is comprised of 495 amino acids and contains six asparagine-linked glycosylation sites, four of which carry a bis mannose-6-phosphate manose7 oligosaccharide for specific cellular recognition. Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family.
Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine 4-sulfatase. The sulfatase activity deficiency results in the accumulation of the GAG substrate dermatan sulfate, throughout the body. This accumulation leads to widespread cellular, tissue, and organ dysfunction. Arylsulfatase B Galsulfase is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. Arylsulfatase B Galsulfase uptake by cells into lysosomes is most likely mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of galsulfase to specific mannose-6-phosphate receptors.
Trade Name | Arylsulfatase B Galsulfase |
Availability | Prescription only |
Generic | Galsulfase |
Galsulfase Other Names | Arylsulfatase B galsulfase, Galsulfasa, Galsulfase, Galsulfase (genetical recombination) |
Related Drugs | Naglazyme |
Type | |
Formula | C2534H3851N691O719S16 |
Weight | 56012.6 Da |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Arylsulfatase B Galsulfase is a recombinant human enzyme used as replacement enzyme therapy for the treatment of of adults and children with Mucopolysaccharidosis VI, a rare genetic disorder caused by a deficiency of a lysosomal enzyme.
For the treatment of adults and children with Mucopolysaccharidosis VI.
Arylsulfatase B Galsulfase is also used to associated treatment for these conditions: Mucopolysaccharidosis VI
How Arylsulfatase B Galsulfase works
Arylsulfatase B Galsulfase supplies recombinant-engineered galsulfase, a normal variant form of the polymorphic human enzyme, N-acetylgalactosamine 4-sulfatase. It is a lysosomal hydrolase that catalyzes the cleavage of the sulfate ester from terminal N-acetylgalactosamine 4-sulfate residues of GAG chondroitin 4-sulfate and dermatan sulfate. Increased catabolism of GAG in turn reduces systemic dermatan sulfate accumulation, thereby reducing the primary symptoms of MPS VI.
Toxicity
There is no experience with overdose of galsulfase.
Food Interaction
No interactions found.Arylsulfatase B Galsulfase Disease Interaction
Volume of Distribution
Week 1: 56-323 mL/kg and 59-2799 mL/kg by week 24
Half Life
9 (6 to 21) minutes during the first week of treatment, 26 (8 to 40) minutes by the 24th week.
Innovators Monograph
You find simplified version here Arylsulfatase B Galsulfase